

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Attorney Reference: 121778-04353859

Applicant: Andreas Bergmann

Application Serial No. 10/516,619

Filing Date: December 3, 2004

Date: May 25, 2005

Page 1 of 1

Examiner: (unassigned)

Group Art Unit: (unassigned)

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
TM	AR	5,639,617	Bohuon			
TM	BR	6,756,483	Bergmann et al.			
	CR					

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country		Translation Readily Available		English Abstract	
						Enclosed	No	Enclosed	No
TM	DR	DE 42 27 454 C1	02/1994	Germany	* see US equivalent above		X	X	
TM	ER	EP 0 656 121 B1	03/1998	Europe					
TM	FR	DE 198 47 690 A1	04/2000	Germany	* see US equivalent above		X	X	
TM	GR	WO 00/22439	04/2000	International			X	X	
	HR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

TM	IR	Maysinger, D. et al., "Effects of treatment with microencapsulated monosialoganglioside GM1 on cortical and striatal acetylcholine release in rats with cortical devascularizing lesions," <i>Neuroscience Letters</i> , vol. 118 (1990) pp. 252-256.
TM	JR	Reinhart, K. et al., "Sepsis und septischer Schock," <i>Intensivmedizin</i> , Georg Thieme Verlag, Stuttgart (2001) pp. 756-760.
TM	KR	Assicot, M. et al., "High serum procalcitonin concentrations in patients with sepsis and infection," <i>The Lancet</i> , vol. 341, no. 8844 (2/27/93) pp. 515-518.
TM	LR	Panacek, E.A., "Anti-TNF strategies," <i>Journal für Anästhesie und Intensivbehandlung</i> , (2/2001) pp. 4-5.
TM	MR	Calandra, T. et al., "Protection from septic shock by neutralization of macrophage migration inhibitory factor," <i>Nature Medicine</i> , vol. 6, no. 2 (2/2000) pp. 164-170.
TM	NR	Garber, K., "Protein C may be sepsis solution," <i>Nature Biotechnology</i> , vol. 18 (9/2000) pp. 917-918.
TM	OR	Pross, H. et al., "Role of Natural Killer Cells in Cancer," <i>Nat Immun</i> , vol. 12 (1993) pp. 279-292.
TM	PR	Lanier, L. et al., "Arousal and inhibition of human NK cells," <i>Immunological Reviews</i> , vol. 155 (1997) pp. 145-154.
TM	QR	Fujii, Y. et al., "IgG Antibodies to AsialoGM1 Are More Sensitive than IgM Antibodies to Kill <i>in vivo</i> Natural Killer Cells and Prematured Cytotoxic T Lymphocytes of Mouse Spleen," <i>Microbiol. Immunol.</i> , vol. 34, no. 6 (1990) pp. 533-542.
TM	RR	Saijo, N. et al., "Analysis of Metastatic Spread and Growth of Tumor Cells in Mice with Depressed Natural Killer Activity by Anti-asialo GM1 Antibody or Anticancer Agents," <i>Cancer Research Clinical Oncology</i> , vol. 107 (1984) pp. 157-163.
TM	SR	Lanier, L., "NK Cell Receptors," <i>Annu. Rev. Immunol.</i> , vol. 16 (1998), pp. 359-393.
TM	TR	Habu, S. et al., "Role of Natural Killer Cells against Tumor Growth in Nude Mice - A Brief Review," <i>J Exp Clin Med.</i> , vol. 8, no. 5, 6 (1983), pp. 465-468.
TM	UR	Whiteside, T. et al., "The role of natural killer cells in immune surveillance of cancer," <i>Current Opinion in Immunology</i> , vol. 7 (1995), pp. 704-710.
TM	VR	Timonen, T. et al., "Natural killer cell-target cell interactions," <i>Current Opinion in Cell Biology</i> , vol. 9 (1997) pp. 667-673.
TM	WR	International Search Report from PCT/EP2003/003448 issued 6/17/03

Examiner /Traviss McIntosh III/ (09/11/2006)

Date Considered: 09/11/2006

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.